Clinical Trial Update: GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study [Phase 3]

View source ↗

Summary

Phase 3 trial update on GLASSIA assessing safety, immunogenicity, and bronchoalveolar lavage in alpha-1 antitrypsin deficiency has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alpha1-antitrypsin Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2021-10-14